HLB Life Science

At a glance

HLB Life Science filed 42 disclosures in the last 12 months, including 4 insider, 3 issuance and 1 5% holder. The most recent key filing was on Jul 1.

Revenue for 2025 was ₩45.8B, up 39.6% on 2024. It made an operating loss of ₩22B. Debt was 61% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩29.9B and operating loss of ₩14B.

The 2025 annual report lists 180 employees with an average tenure of 2.1 years and average pay of ₩48.4M, #1522 of 1,829 listed companies by average pay. Its 7 directors and auditors were paid ₩200.5M each on average. It paid no cash dividend for 2025. 에이치엘비(주) and related parties held 19.61% at year end.

From the 2025 annual report

Staff: 180 (96 men, 84 women), of whom 17 on fixed-term contracts. Total pay for the year: ₩8.8B. Directors and auditors: 7, paid ₩1.4B in total.

No cash dividend was paid for 2025.

Largest shareholder

에이치엘비(주) holds 16.98%; with 1 related party the group holds 19.61% of common shares at year end.

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary